Abstract
The purine nucleoside analog (PNA) - cladribine (2-CdA, 2-chlorodeoxyadenosine) is a cytotoxic agent of high efficacy in lymphoid and myeloid malignancies. This drug was approved by the FDA for treatment of hairy cell leukemia and in some European countries for treatment of refractory/relapsed chronic lymphocytic leukemia. 2-CdA is usually administered as continuous or intermittent intravenous infusion. Recently however, new formulations of this agent has been developed for subcutaneous and oral administration. In contrast to other PNA, 2-CdA is equally cytotoxic to both proliferating and quiescent cells and several pathways may be responsible for the mechanism of its action. In addition, recent data indicate that 2-CdA combined with other cytotoxic agents and monoclonal antibodies show synergistic proapoptotic and cytotoxic activity on lymphoid and myeloid neoplastic cells. This review article summarizes recent achievements in the understanding of 2-CdA mechanism of action, pharmacokinetics of different pharmaceutical formulations and its approved and possible future applications in the treatment of hematological malignancies. The most important recent patents concerning oral formulations of 2-CdA have been presented.
Keywords: Cladribine, oral, subcutaneous, pharmacokinetics, leukemia, lymphoma, systemic mastocytosis, Langerhans cell histiocytosis, acute myeloid leukemia
Recent Patents on Anti-Cancer Drug Discovery
Title: Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Volume: 1 Issue: 1
Author(s): Tadeusz Robak, Anna Korycka and Ewa Robak
Affiliation:
Keywords: Cladribine, oral, subcutaneous, pharmacokinetics, leukemia, lymphoma, systemic mastocytosis, Langerhans cell histiocytosis, acute myeloid leukemia
Abstract: The purine nucleoside analog (PNA) - cladribine (2-CdA, 2-chlorodeoxyadenosine) is a cytotoxic agent of high efficacy in lymphoid and myeloid malignancies. This drug was approved by the FDA for treatment of hairy cell leukemia and in some European countries for treatment of refractory/relapsed chronic lymphocytic leukemia. 2-CdA is usually administered as continuous or intermittent intravenous infusion. Recently however, new formulations of this agent has been developed for subcutaneous and oral administration. In contrast to other PNA, 2-CdA is equally cytotoxic to both proliferating and quiescent cells and several pathways may be responsible for the mechanism of its action. In addition, recent data indicate that 2-CdA combined with other cytotoxic agents and monoclonal antibodies show synergistic proapoptotic and cytotoxic activity on lymphoid and myeloid neoplastic cells. This review article summarizes recent achievements in the understanding of 2-CdA mechanism of action, pharmacokinetics of different pharmaceutical formulations and its approved and possible future applications in the treatment of hematological malignancies. The most important recent patents concerning oral formulations of 2-CdA have been presented.
Export Options
About this article
Cite this article as:
Robak Tadeusz, Korycka Anna and Robak Ewa, Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (1) . https://dx.doi.org/10.2174/157489206775246467
DOI https://dx.doi.org/10.2174/157489206775246467 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Rheumatologic Aspects of the COVID-19 Pandemic: A Practical Resource for Physicians in Kuwait and the Gulf region as Recommended by the Kuwait Association of Rheumatology
Current Rheumatology Reviews MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments
Current Medicinal Chemistry Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer
Current Cancer Therapy Reviews Proteomic Analysis of Mitochondria in Raji Cells Following Exposure to Radiation: Implications for Radiotherapy Response
Protein & Peptide Letters Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma
Current Cancer Drug Targets Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Current Cancer Drug Targets Immunotherapy and Targeted Therapy Combinations in Renal Cancer
Current Clinical Pharmacology Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials
Anti-Cancer Agents in Medicinal Chemistry Pterostilbene as a Potential Novel Telomerase Inhibitor: Molecular Docking Studies and Its in vitro Evaluation
Current Pharmaceutical Biotechnology Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes
Current Drug Targets Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Transplantation and Other Uses of Human Umbilical Cord Blood and Stem Cells
Current Pharmaceutical Design